Related Articles
A combined analysis of two pivotal randomized trials of a single dose of pegfilgrastim per chemotherapy cycle and daily Filgrastim in patients with stage II-IV breast cancer
Effects of primary granulocyte‑colony stimulating factor prophylaxis on the incidence of febrile neutropenia in patients with germ cell tumors
Use of granulocyte colony-stimulating factor: A survey among Italian medical oncologists
Outpatient management without initial assessment for febrile patients undergoing adjuvant chemotherapy for breast cancer
Chemotherapy continuity and incidence of febrile neutropenia with CHOP therapy in an outpatient setting